A molecular case report: Functional assay of tyrosine kinase inhibitors in cells from a patient’s primary renal cell carcinoma

Current therapies for Renal Cell Carcinoma favor vascular endothelial growth factor receptor (VEGF-R) tyrosine kinase (TK) inhibitors (TKIs). In theory, these are most applicable in tumors that have lost VHL-with subsequent stabilization of HIF and upregulation of VEGF. A subset of patients harbor p...

Descripción completa

Detalles Bibliográficos
Autores principales: Kulesz-Martin, Molly, Lagowski, James, Olson, Susan, Wortham, Aaron, West, Toni, Thomas, George, Ryan, Christopher W., Tyner, Jeffrey W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3572006/
https://www.ncbi.nlm.nih.gov/pubmed/23192268
http://dx.doi.org/10.4161/cbt.22960

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3572006/
https://www.ncbi.nlm.nih.gov/pubmed/23192268
http://dx.doi.org/10.4161/cbt.22960

Ejemplares similares